Search

Your search keyword '"Yalniz, Fevzi"' showing total 192 results
Start Over Author "Yalniz, Fevzi"
192 results on '"Yalniz, Fevzi"'

1. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Author

Weisel, Katja, Krishnan, Amrita, Schecter, Jordan M., Vogel, Martin, Jackson, Carolyn C., Deraedt, William, Yeh, Tzu-min, Banerjee, Arnob, Yalniz, Fevzi, Nesheiwat, Tonia, Van Sanden, Suzy, Diels, Joris, Valluri, Satish, Usmani, Saad Z., Berdeja, Jesus G., Jagannath, Sundar, and Martin, Tom

Published
2022
Full Text
View/download PDF

2. Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients.

Author

Yalniz, Fevzi F., Johnson, Anna, Alnimer, Yanal, Chahine, Zena, Morris, Trevor, Yadav, Rina, Taj, Hiffsa, Iragavarapu, Chaitanya, Munker, Reinhold, Monohan, Gregory, Wai, Sainan, Zhang, Shulin, Nozad, Sahar, and Qasrawi, Ayman

Subjects
*ACUTE myeloid leukemia, *GENETIC profile, *OVERALL survival, *GENETIC mutation, *OBESITY
Abstract

ABSTRACT Background Methods Results Conclusions The molecular architecture of acute myeloid leukemia (AML) is heterogeneous. Obesity has been identified as a risk factor for the development of AML. There remains a scarcity of data elucidating the specific genetic profile of AML in obese patients.We conducted a review of adult patients treated at our institution for newly diagnosed AML from January 1, 2017, to January 1, 2023. Obesity is defined as BMI > 30 kg/m2. Demographic, clinical, laboratory, and pathologic data were collected retrospectively. The primary outcome of interest was the molecular features of obese compared to non‐obese AML patients. The secondary outcome was overall survival (OS). Inverse probability of treatment weights (IPTW) used to balance both groups on several confounding variables.A total of 185 patients were included in the analysis. 90 (49%) were obese. Compared with non‐obese patients, obese patients were younger and more likely to be females (55 vs. 63, p = 0.04, 55% vs. 38%, p value, p = 0.02, respectively). After matching on age, gender, and ethnicity, obese patients exhibit lower rates of total number of gene mutations (median 2.7 vs. 3.2, p = 0.05), significantly lower rates of mutations in transcriptional factor genes (15.7% vs. 33.2%, p = 0.01), and near‐significant in spliceosome genes (12% vs. 22.3%, p = 0.08), and higher rates of NPM1 mutation (23.3% vs. 12.6%, p = 0.08). Median OS was not significantly different in the matched cohort.The molecular features of obese AML patients significantly differ from non‐obese counterparts. These findings suggest distinct underlying mechanisms in leukemogenesis in obese patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Author

Duchmann, Matthieu, Yalniz, Fevzi, Sanna, Alessandro, Sallman, David, Coombs, Catherine, Renneville, Aline, Kosmider, Olivier, Braun, Thorsten, Platzbecker, Uwe, Willems, Lise, Adès, Lionel, Fontenay, Michaela, Rampal, Raajit, Padron, Eric, Droin, Nathalie, Preudhomme, Claude, Santini, Valeria, Patnaik, Mrinal, Fenaux, Pierre, Solary, Eric, and Itzykson, Raphael

Subjects
Chronic myelomonocytic leukemia, Hypomethylating agents, Prognosis, Somatic mutations, Aged, Azacitidine, Core Binding Factor Alpha 2 Subunit, DNA-Binding Proteins, Decitabine, Dioxygenases, Female, High-Throughput Nucleotide Sequencing, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Mutation, Proto-Oncogene Proteins, Repressor Proteins
Abstract

Somatic mutations contribute to the heterogeneous prognosis of chronic myelomonocytic leukemia (CMML). Hypomethylating agents (HMAs) are active in CMML, but analyses of small series failed to identify mutations predicting response or survival. We analyzed a retrospective multi-center cohort of 174 CMML patients treated with a median of 7 cycles of azacitidine (n = 68) or decitabine (n = 106). Sequencing data before treatment initiation were available for all patients, from Sanger (n = 68) or next generation (n = 106) sequencing. Overall response rate (ORR) was 52%, including complete response (CR) in 28 patients (17%). In multivariate analysis, ASXL1 mutations predicted a lower ORR (Odds Ratio [OR] = 0.85, p = 0.037), whereas TET2mut/ASXL1wt genotype predicted a higher CR rate (OR = 1.18, p = 0.011) independently of clinical parameters. With a median follow-up of 36.7 months, overall survival (OS) was 23.0 months. In multivariate analysis, RUNX1mut (Hazard Ratio [HR] = 2.00, p = .011), CBLmut (HR = 1.90, p = 0.03) genotypes and higher WBC (log10(WBC) HR = 2.30, p = .005) independently predicted worse OS while the TET2mut/ASXL1wt predicted better OS (HR = 0.60, p = 0.05). CMML-specific scores CPSS and GFM had limited predictive power. Our results stress the need for robust biomarkers of HMA activity in CMML and for novel treatment strategies in patients with myeloproliferative features and RUNX1 mutations.

Published
2018

5. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation

Author

Yalniz, Fevzi F., Greenbaum, Uri, Pasvolsky, Oren, Milton, Denái R., Kanagal-Shamanna, Rashmi, Ramdial, Jeremy, Srour, Samer, Mehta, Rohtesh, Alousi, Amin, Popat, Uday R., Nieto, Yago, Kebriaei, Partow, Al-Atrash, Gheath, Oran, Betul, Hosing, Chitra, Ahmed, Sairah, Champlin, Richard E., Shpall, Elizabeth J., Qazilbash, Muzaffar H., and Bashir, Qaiser

Published
2024
Full Text
View/download PDF

6. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia

Author

Yalniz, Fevzi F., Saliba, Rima M., Greenbaum, Uri, Ramdial, Jeremy, Popat, Uday, Oran, Betul, Alousi, Amin, Olson, Amanda, Alatrash, Gheath, Marin, David, Rezvani, Katayoun, Hosing, Chitra, Im, Jin, Mehta, Rohtesh, Qazilbash, Muzaffar, Joseph, Jacinth Joy, Rondon, Gabriela, Kanagal-Shamanna, Rashmi, Shpall, Elizabeth, Champlin, Richard, and Kebriaei, Partow

Published
2021
Full Text
View/download PDF

7. CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity

Author

Greenbaum, Uri, Strati, Paolo, Saliba, Rima M., Torres, Janet, Rondon, Gabriela, Nieto, Yago, Hosing, Chitra, Srour, Samer A., Westin, Jason, Fayad, Luis E., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Nastoupil, Loretta J., Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Flowers, Christopher R., Tummala, Sudhakar, Ramdial, Jeremy L., Yalniz, Fevzi F., Hawkins, Misha, Rezvani, Katayoun, Champlin, Richard E., Shpall, Elizabeth J., Neelapu, Sattva S., Kebriaei, Partow, and Ahmed, Sairah

Published
2021
Full Text
View/download PDF

14. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation

Author

Yalniz, Fevzi F., primary, Greenbaum, Uri, additional, Pasvolsky, Oren, additional, Milton, Denái R., additional, Kanagal-Shamanna, Rashmi, additional, Ramdial, Jeremy, additional, Srour, Samer, additional, Mehta, Rohtesh, additional, Alousi, Amin, additional, Popat, Uday R., additional, Nieto, Yago, additional, Kebriaei, Partow, additional, Al-Atrash, Gheath, additional, Oran, Betul, additional, Hosing, Chitra, additional, Ahmed, Sairah, additional, Champlin, Richard E., additional, Shpall, Elizabeth J., additional, Qazilbash, Muzaffar H., additional, and Bashir, Qaiser, additional

Published
2023
Full Text
View/download PDF

15. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec

Author

Eskazan, Ahmet Emre, Sadri, Sevil, Keskin, Dilek, Ayer, Mesut, Kantarcioglu, Bulent, Demirel, Naciye, Aydin, Demet, Aydinli, Fuat, Yokus, Osman, Ozunal, Isil Erdogan, Berk, Selin, Yalniz, Fevzi Firat, Elverdi, Tugrul, Salihoglu, Ayse, Ar, Muhlis Cem, Ongoren, Seniz, Baslar, Zafer, Aydin, Yildiz, Tuzuner, Nukhet, Ozbek, Ugur, and Soysal, Teoman

Published
2017
Full Text
View/download PDF

17. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

Author

Abou Dalle, Iman, Ghorab, Ahmad, Patel, Keyur, Wang, Xuemei, Hwang, Hyunsoo, Cortes, Jorge, Issa, Ghayas C., Yalniz, Fevzi, Sasaki, Koji, Chihara, Dai, Price, Allyson, Kadia, Tapan, Pemmaraju, Naveen, Daver, Naval, DiNardo, Courtney, Ravandi, Farhad, Kantarjian, Hagop M., and Borthakur, Gautam

Published
2020
Full Text
View/download PDF

18. Cytogenetic profile of adult AML patients in Turkey: a single center study with comprehensive comparison with literature

Author

Cirakoglu, Ayse, Dilhan Kuru, Rahiye, Yilmaz, Sukriye, Deviren, Ayhan, Ongoren, Seniz, Firat Yalniz, Fevzi, Keskin, Dilek, Emre Eskazan, Ahmet, Salihoglu, Ayse, Cem Ar, Muhlis, Sahin, Serdar, Aydin, Yildiz, Hacihanefioglu, Seniha, Baslar, Zafer, Soysal, Teoman, and Tarkan Arguden, Yelda

Subjects
Acute myeloid leukemia, cytogenetics, chromosomal abnormalities, adult, General Medicine
Abstract

Background: Cytogenetic findings are important prognostic factors in acute myeloid leukemia. Large systematic data about chromosomal characteristics of Turkish AML patients have not been reported to date. Objectives: The karyotypic profiles of 157 adult AML patients were evaluated retrospectively and compared with other reports from different populations. Methods: Cytogenetics analyses were performed on bone marrow samples using G-banding. Patients were categorized according to their cytogenetic results into four groups with the addition of a normal karyotyped group to the favorable, intermediate and adverse groups of European Leukemia Network. Results: Cytogenetic analyses were carried out successfully in 138 patients (88%). Abnormal karyotypes were found in 79 (57.2%) patients of which 13 (9.4%) were in favorable, 37 (26.8%) in intermediate and 29 (21%) in adverse groups. t(8;21) (5%) was the most common favorable abnormality while monosomal karyotypes (15.9%) in adverse group. Conclusion: This single center study is the most comprehensive study about the cytogenetic profile of acute myeloid leukemia in Turkey with comparison of other population-based studies. While there were similarities and differences with different publications, our results did not show a marked tendency to the findings of any specific geographic region. Keywords: Acute myeloid leukemia; cytogenetics; chromosomal abnormalities; adult.

Published
2022
Full Text
View/download PDF

23. P-241: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the Flatiron database

Author

Dhakal, Binod, primary, Einsele, Hermann, additional, Schecter, Jordan, additional, Deraedt, William, additional, Lendvai, Nikoletta, additional, Slaughter, Ana, additional, Lonardi, Carolina, additional, Nair, Sandhya, additional, He, Jianming, additional, Voelker, Jennifer, additional, Cost, Patricia, additional, Valluri, Satish, additional, Pacaud, Lida, additional, Yalniz, Fevzi, additional, and Yong, Kwee, additional

Published
2022
Full Text
View/download PDF

24. P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database

Author

Dhakal, Binod, primary, Einsele, Hermann, additional, Potluri, Ravi, additional, Schecter, Jordan, additional, Deraedt, William, additional, Lendvai, Nikoletta, additional, Slaughter, Ana, additional, Lonardi, Carolina, additional, Nair, Sandhya, additional, He, Jianming, additional, Voelker, Jennifer, additional, Cost, Patricia, additional, Valluri, Satish, additional, Yalniz, Fevzi, additional, Pacaud, Lida, additional, and Yong, Kwee, additional

Published
2022
Full Text
View/download PDF

25. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia

Author

Ozturk, Ahmet, Kucukardali, Yasar, Tangi, Fatih, Erikci, Alev, Uzun, Gunalp, Bashekim, Cınar, Sen, Huseyin, Terekeci, Hakan, Narin, Yavuz, Ozyurt, Mustafa, Ozkan, Sezai, Sayan, Ozkan, Rodop, Osman, Nalbant, Selim, Sıldıroglu, Onur, Yalnız, Fevzi Firat, Senkal, İbrahim Volkan, Sabuncu, Hilmi, and Oktenli, Cagatay

Published
2012
Full Text
View/download PDF

26. Cartitude-5: A Randomized, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Intended for Transplant

Author

Agha, Mounzer, primary, Dhakal, Binod, additional, Dytfeld, Dominik, additional, Manier, Salomon, additional, Delforge, Michel, additional, Kuppens, Steven, additional, Afifi, Salma, additional, Deraedt, William, additional, Taraseviciute-Morris, Agne, additional, Schecter, Jordan M, additional, Gilbert, Jane, additional, Yalniz, Fevzi, additional, Florendo, Erika, additional, Pacaud, Lida, additional, Hungria, Vania, additional, Usmani, Saad Z., additional, and Mateos, Maria-Victoria, additional

Published
2022
Full Text
View/download PDF

27. Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

Author

Dytfeld, Dominik, primary, Dhakal, Binod, additional, Agha, Mounzer, additional, Manier, Salomon, additional, Delforge, Michel, additional, Kuppens, Steven, additional, Afifi, Salma, additional, Deraedt, William, additional, Taraseviciute-Morris, Agne, additional, Schecter, Jordan M., additional, Gilbert, Jane, additional, Yalniz, Fevzi, additional, Florendo, Erika, additional, Pacaud, Lida, additional, Hungria, Vania, additional, Usmani, Saad Z., additional, and Mateos, Maria-Victoria, additional

Published
2021
Full Text
View/download PDF

32. Copy Number Variations in Adult Patients with Chronic Immune Thrombocytopenia

Author

Yucesan Emrah, Hatirnaz Ng Ozden, Yalniz Fevzi Firat, Yilmaz Hulya, Salihoglu Ayse, Sudutan Tugce, Eskazan Ahmet Emre, Ongoren Seniz, Baslar Zafer, Soysal Teoman, Ozbek Ugur, Sayitoglu Muge, and Ar Muhlis Cem

Subjects
immune system diseases, hemic and lymphatic diseases, Immune thrombocytopenia, copy number variation, SNP Array
Abstract

In this report we identified CNV regions unique to adult ITP patients. Despite several studies the genetic background of ITP is still unclear. There are studies on pediatric cases, describing several genes associated with the disease, but the data is still limited. Here, we aimed to identify regions that may play a role in the pathogenesis of adult ITP by SNP array technology. Our findings support the idea that ITP is not only clinically but also genetically heterogeneous and genetic modifiers play an important role in the development of the disease. We believe that this data will provide important bases for the future studies to enlighten ITP pathogenesis.

Published
2020
Full Text
View/download PDF

33. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)

Author

Greenbaum, Uri, primary, Strati, Paolo, additional, Saliba, Rima M., additional, Torres, Janet, additional, Rondon, Gabriela, additional, Nieto, Yago, additional, Hosing, Chitra, additional, Srour, Samer A., additional, Westin, Jason, additional, Fayad, Luis, additional, Lee, Hun Ju, additional, Iyer, Swaminathan P, additional, Nastoupil, Loretta J., additional, Parmar, Simrit, additional, Rodriguez, Maria Alma, additional, Samaniego, Felipe, additional, Steiner, Raphael Eric, additional, Wang, Michael, additional, Pinnix, Chelsea C., additional, Flowers, Christopher, additional, Tummala, Sudhakar, additional, Ramdial, Jeremy, additional, Yalniz, Fevzi F., additional, Hawkins, Misha, additional, Rezvani, Katayoun, additional, Champlin, Richard E., additional, Shpall, Elizabeth J., additional, Neelapu, Sattva S., additional, Kebriaei, Partow, additional, and Ahmed, Sairah, additional

Published
2020
Full Text
View/download PDF

34. Copy-number variations in adult patients with chronic immune thrombocytopenia

Author

Yucesan, Emrah, primary, Hatirnaz Ng, Ozden, additional, Yalniz, Fevzi Firat, additional, Yilmaz, Hulya, additional, Salihoglu, Ayse, additional, Sudutan, Tugce, additional, Eskazan, Ahmet Emre, additional, Ongoren, Seniz, additional, Baslar, Zafer, additional, Soysal, Teoman, additional, Ozbek, Ugur, additional, Sayitoglu, Muge, additional, and Ar, M. Cem, additional

Published
2020
Full Text
View/download PDF

35. AML-317: Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Myeloid Leukemia

Author

Yalniz, Fevzi, primary, Saliba, Rima, additional, Greenbaum, Uri, additional, Ramdial, Jeremy, additional, Alousi, Amin, additional, Joseph, Jacinth, additional, Olson, Amanda, additional, Alatrash, Gheath, additional, Marin, David, additional, Rezvani, Katayoun, additional, Hosing, Chitra, additional, Im, Jin, additional, Shpall, Elizabeth, additional, Mehta, Rohtesh, additional, Qazilbash, Muzaffar, additional, Popat, Uday, additional, Oran, Betul, additional, Champlin, Richard, additional, and Kebriaei, Partow, additional

Published
2020
Full Text
View/download PDF

36. Peripheral Blood Stem Cell Mobilization for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Growth Factors Only Vs. Growth Factors + Chemotherapy

Author

Ramdial, Jeremy, primary, Ma, Junsheng, additional, Milton, Denai R, additional, Delgado, Ruby, additional, Bashir, Qaiser, additional, Srour, Samer A., additional, Saini, Neeraj, additional, Nieto, Yago, additional, Hosing, Chitra M., additional, Popat, Uday R., additional, Lee, Hans C., additional, Patel, Krina, additional, Yalniz, Fevzi Firat, additional, Champlin, Richard E., additional, and Qazilbash, Muzaffar H., additional

Published
2020
Full Text
View/download PDF

37. Significance of minimal residual disease monitoring by real‐time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes

Author

Yalniz, Fevzi F., primary, Patel, Keyur P., additional, Bashir, Qaiser, additional, Marin, David, additional, Ahmed, Sairah, additional, Alousi, Amin M., additional, Chen, Julianne, additional, Ciurea, Stefan O., additional, Rezvani, Katy, additional, Popat, Uday R., additional, Shpall, Elizabeth J., additional, Champlin, Richard E., additional, and Oran, Betül, additional

Published
2020
Full Text
View/download PDF

38. 220 - Cartitude-5: A Randomized, Phase 3 Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Intended for Transplant

Author

Agha, Mounzer, Dhakal, Binod, Dytfeld, Dominik, Manier, Salomon, Delforge, Michel, Kuppens, Steven, Afifi, Salma, Deraedt, William, Taraseviciute-Morris, Agne, Schecter, Jordan M, Gilbert, Jane, Yalniz, Fevzi, Florendo, Erika, Pacaud, Lida, Hungria, Vania, Usmani, Saad Z., and Mateos, Maria-Victoria

Published
2022
Full Text
View/download PDF

39. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation

Author

Yalniz, Fevzi F., primary, Saliba, Rima M., primary, Yucel, Orhan K., primary, Garcia-Manero, Guillermo, primary, Ramdial, Jeremy, primary, Popat, Uday, primary, Ciurea, Stefan O., primary, Kebriaei, Partow, primary, Alousi, Amin M., primary, Alatrash, Gheath, primary, Bashir, Qaiser, primary, Hosing, Chitra, primary, Marin, David, primary, Mehta, Rohtesh, primary, Olson, Amanda L., primary, Rezvani, Katayoun, primary, Shpall, Elizabeth J., primary, Rondon, Gabriela, primary, Champlin, Richard E., primary, and Oran, Betul, primary

Published
2019
Full Text
View/download PDF

40. A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy

Author

Yalniz, Fevzi F., primary, Berdeja, Jesus G., additional, Maris, Michael B., additional, Lyons, Roger M., additional, Reeves, James A., additional, Essell, James H., additional, Patel, Prapti, additional, Sekeres, Mikkael, additional, Hughes, Amanda, additional, Mappa, Silvia, additional, and Garcia‐Manero, Guillermo, additional

Published
2019
Full Text
View/download PDF

41. Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

Author

Yalniz, Fevzi, primary, Abou Dalle, Iman, additional, Kantarjian, Hagop, additional, Borthakur, Gautam, additional, Kadia, Tapan, additional, Patel, Keyur, additional, Loghavi, Sanam, additional, Garcia‐Manero, Guillermo, additional, Sasaki, Koji, additional, Daver, Naval, additional, DiNardo, Courtney, additional, Pemmaraju, Naveen, additional, Short, Nicholas J., additional, Yilmaz, Musa, additional, Bose, Prithviraj, additional, Naqvi, Kiran, additional, Pierce, Sherry, additional, Nogueras González, Graciela M., additional, Konopleva, Marina, additional, Andreeff, Michael, additional, Cortes, Jorge, additional, and Ravandi, Farhad, additional

Published
2019
Full Text
View/download PDF

42. A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.

Author

Yalniz, Fevzi F., Berdeja, Jesus G., Maris, Michael B., Lyons, Roger M., Reeves, James A., Essell, James H., Patel, Prapti, Sekeres, Mikkael, Hughes, Amanda, Mappa, Silvia, and Garcia‐Manero, Guillermo

Subjects
*MYELODYSPLASTIC syndromes, *TERMINATION of treatment, *DISEASE progression, *BONE marrow, *ADVERSE health care events
Abstract

Summary: Hypomethylating agents (HMAs) are standard of care for higher‐risk myelodysplastic syndromes (MDS). However, less than half of patients achieve objective responses and most eventually lose their response. Pracinostat is a pan‐histone deacetylase inhibitor with demonstrated activity in advanced myeloid malignancies. This phase II study explored the benefit of adding pracinostat to HMAs in MDS patients who did not respond to single‐agent HMA treatment. The goal was to estimate the clinical improvement rate [complete remission (CR), marrow CR, partial response (PR) and haematological improvement]. Group 1 included patients with primary/secondary HMA failures; Group 2 included those who did not achieve response but had stable disease (SD) after single‐agent HMAs. Forty‐five patients (39 Group 1, 6 Group 2) received a median of 3 cycles. Among all patients, 1 (2%) had CR, 7 (16%) had marrow CR and 18 (40%) had SD; disease progression occurred in 3 (7%). Median overall survival was 5·7/5·6 months for Group 1/2. Grade ≥3 adverse events occurred in 38 patients (84%) leading to treatment discontinuation in 12 (33%). Adding pracinostat to HMAs did not improve outcomes in patients previously treated with HMAs. Frequent dose modifications/early discontinuation resulted in suboptimal drug exposure. A reduced pracinostat dose may improve tolerability and efficacy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

43. Potential Predictors of Induction Failure and Complete Remission Duration in FLT3-ITD Mutated Acute Myeloid Leukemia

Author

Yalniz, Fevzi, primary, Kantarjian, Hagop M., additional, Borthakur, Gautam, additional, Kadia, Tapan M., additional, Daver, Naval G., additional, Pemmaraju, Naveen, additional, Konopleva, Marina Y., additional, Garcia-Manero, Guillermo, additional, Takahashi, Koichi, additional, DiNardo, Courtney D., additional, Bose, Prithviraj, additional, Andreeff, Michael, additional, Ravandi, Farhad, additional, and Cortes, Jorge E., additional

Published
2018
Full Text
View/download PDF

44. Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib

Author

Yalniz, Fevzi, primary, Kantarjian, Hagop M., additional, Kadia, Tapan M., additional, Garcia-Manero, Guillermo, additional, Patel, Keyur, additional, Loghavi, Sanam, additional, Sasaki, Koji, additional, Daver, Naval G., additional, DiNardo, Courtney D., additional, Pemmaraju, Naveen, additional, Short, Nicholas J, additional, Yilmaz, Musa, additional, Bose, Prithviraj, additional, Naqvi, Kiran, additional, Pierce, Sherry A., additional, Cortes, Jorge E., additional, and Ravandi, Farhad, additional

Published
2018
Full Text
View/download PDF

45. Characteristics and outcomes of acute myeloid leukemia (AML) with extramedullary disease (EMD).

Author

Yalniz, Fevzi Firat, primary, Cortes, Jorge E., additional, Borthakur, Gautam, additional, Garcia-Manero, Guillermo, additional, Kadia, Tapan M., additional, Konopleva, Marina, additional, Dinardo, Courtney Denton, additional, Daver, Naval Guastad, additional, Wierda, William G., additional, Verstovsek, Srdan, additional, Pemmaraju, Naveen, additional, Estrov, Zeev, additional, Ravandi, Farhad, additional, and Kantarjian, Hagop M., additional

Published
2018
Full Text
View/download PDF

46. A pilot trial of anti-KIR antibody with or without 5-azacitidine for myelodysplastic syndrome.

Author

Yalniz, Fevzi Firat, primary, Daver, Naval Guastad, additional, Kornblau, Steven Mitchell, additional, Ohanian, Maro, additional, Borthakur, Gautam, additional, Dinardo, Courtney Denton, additional, Konopleva, Marina, additional, Burger, Jan Andreas, additional, Gasior, Yvonne, additional, Pierce, Sherry, additional, Kantarjian, Hagop M., additional, and Garcia-Manero, Guillermo, additional

Published
2018
Full Text
View/download PDF

47. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents

Author

Duchmann, Matthieu, primary, Yalniz, Fevzi F., additional, Sanna, Alessandro, additional, Sallman, David, additional, Coombs, Catherine C., additional, Renneville, Aline, additional, Kosmider, Olivier, additional, Braun, Thorsten, additional, Platzbecker, Uwe, additional, Willems, Lise, additional, Adès, Lionel, additional, Fontenay, Michaela, additional, Rampal, Raajit, additional, Padron, Eric, additional, Droin, Nathalie, additional, Preudhomme, Claude, additional, Santini, Valeria, additional, Patnaik, Mrinal M., additional, Fenaux, Pierre, additional, Solary, Eric, additional, and Itzykson, Raphael, additional

Published
2018
Full Text
View/download PDF

49. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature

Author

Ongoren, Seniz, primary, Eskazan, Ahmet Emre, additional, Suzan, Veysel, additional, Savci, Sercan, additional, Erdogan Ozunal, Isil, additional, Berk, Selin, additional, Yalniz, Fevzi Fırat, additional, Elverdi, Tugrul, additional, Salihoglu, Ayse, additional, Erbilgin, Yucel, additional, Iseri, Sibel Aylin, additional, Ar, Muhlis Cem, additional, Baslar, Zafer, additional, Aydin, Yildiz, additional, Tuzuner, Nukhet, additional, Ozbek, Ugur, additional, and Soysal, Teoman, additional

Published
2017
Full Text
View/download PDF

50. Infectious Complications Associated with Infliximab Therapy for Allogeneic Stem Cell Transplant Patients with Corticosteroid Refractory Acute Graft Versus Host Disease

Author

Yalniz, Fevzi Firat, primary, Hefazi, Mehrdad, additional, McCollough, Kristen, additional, Litzow, Mark R., additional, Hogan, William J., additional, Wolf, Robert, additional, Alkhateeb, Hassan B., additional, Kansagra, Ankit J., additional, Damlaj, Moussab, additional, and Patnaik, Mrinal S., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results